The Medical Letter on Drugs and Therapeutics
Rivaroxaban (Xarelto) - A New Oral Anticoagulant
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved rivaroxaban (Xarelto – Janssen), an oral direct factor Xa inhibitor, for prevention of deep vein thrombosis (DVT) in patients undergoing knee or hip replacement surgery.

CLINICAL STUDIES — A pooled analysis of four randomized, double-blind trials (the RECORD studies1-4) in a total of 12,729 patients undergoing hip or knee arthroplasty found that a composite endpoint of symptomatic venous thromboembolism (VTE) or death occurred in 0.5% of patients taking rivaroxaban 10 mg once daily and in 1% of patients taking the low-molecular weight heparin enoxaparin 40 mg once or 30 mg twice daily, a significant difference. Major bleeding occurred in 0.3% of patients treated with rivaroxaban and in 0.2% of those receiving enoxaparin. Major plus non-major clinically relevant bleeding occurred in 2.8% vs. 2.5%, and any bleeding occurred in 6.6% vs. 6.2%. None ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rivaroxaban (Xarelto) - A New Oral Anticoagulant
Article code: 1371b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian